European neurology · 2009
Interferon-beta(1b) treatment in neuromyelitis optica.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanaka Masami, Tanaka Keiko, Komori Mika
Аннотация
BACKGROUND: The effects of interferon-beta(1b) (IFN-beta(1b)) administration in multiple sclerosis (MS) patients have been confirmed, however, those in neuromyelitis optica (NMO) patients have not been shown. In this study, we assessed the effects of IFN-beta(1b) treatment on disease exacerbation and disability progression in MS or NMO patients.
METHODS: We reviewed a series of 104 consecutive patients with relapsing-remitting MS (RRMS) (69) or NMO (35) treated with IFN-beta(1b) in the MS clinical center of a national hospital in Japan.
RESULTS: The relapse number in the RRMS patients significantly decreased within 1 year after IFN-beta(1b) treatment (p < 0.00001); however, that in the NMO patients did not show a significant decrease (p = 0.5601). The decrease in annualized relapse rates in each RRMS patient after treatment was significant (p < 0.01), but that in each NMO patient was not (p > 0.05). The change in Kurtzke's Expanded Disability Status Scale score 1 year after treatment was higher in the NMO patients than in the RRMS patients (p = 0.0225).
CONCLUSION: In NMO patients, IFN-beta(1b) treatment was not effective in reducing the relapse number and the disability progression.
METHODS: We reviewed a series of 104 consecutive patients with relapsing-remitting MS (RRMS) (69) or NMO (35) treated with IFN-beta(1b) in the MS clinical center of a national hospital in Japan.
RESULTS: The relapse number in the RRMS patients significantly decreased within 1 year after IFN-beta(1b) treatment (p < 0.00001); however, that in the NMO patients did not show a significant decrease (p = 0.5601). The decrease in annualized relapse rates in each RRMS patient after treatment was significant (p < 0.01), but that in each NMO patient was not (p > 0.05). The change in Kurtzke's Expanded Disability Status Scale score 1 year after treatment was higher in the NMO patients than in the RRMS patients (p = 0.0225).
CONCLUSION: In NMO patients, IFN-beta(1b) treatment was not effective in reducing the relapse number and the disability progression.